Adherence and Persistence of Bimatoprost in Prior Latanoprost Users

Document Type


Publication Title

American Journal of Pharmacy Benefits


Objectives: Bimatoprost 0.01%, a newer ophthalmic formulation, was hypothesized to improve adherence and persistence compared with the original bimatoprost 0.03% formulation.

Study Design: A retrospective, observational cohort study was conducted that utilized a pharmacy claims database to examine the adherence to and persistence with prior latanoprost use among patients with glaucoma who were prescribed bimatoprost 0.01% or bimatoprost 0.03% for glaucoma treatment.

Methods: Using pharmacy claims, adherence in 6035 bimatoprost 0.01% patients and 2705 bimatoprost 0.03% patients with prior latanoprost treatment was measured as a proportion of days covered (PDC). Persistence in 7780 bimatoprost 0.01% and 3454 bimatoprost 0.03% latanoprost-experienced patients was measured as the proportion of patients on continuous treatment for up to 12 months.

Results: Adherence to bimatoprost 0.01% was significantly greater than to bimatoprost 0.03% (mean PDC, 0.74 vs 0.68; P <.001). Persistence with bimatoprost 0.01% (52%) was significantly greater than with bimatoprost 0.03% (46%). Analyses conducted by age group (aged <65 and ≥65 years) yielded similar results.

Conclusions: In clinical practice, bimatoprost 0.01% demonstrated superior adherence and persistence compared with bimatoprost 0.03% in latanoprost-experienced patients.

First Page


Last Page


Publication Date